About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Showing: since Aug 17, 2026 (set the dates above to see older items)

Phase 3 studies marked completed, by completion date. Studies whose sponsor is matched to a public company. Change Sponsors to Everyone to include the rest.

Latest clinical trial updates
CompletedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.StudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.EnrolledResultsSource
Nov 4, 2026Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and Gingivitis
NCT07917507 · Plaque, Gingivitis
0.412% stannous fluoride toothpaste and flat trimmed toothb…
CL
Colgate Palmolive
Phase 384—Registry ↗
Oct 29, 2026A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in…
NCT05133531 · Paroxysmal Nocturnal Hemoglobinuria
Ravulizumab, Pozelimab
REGN
Regeneron Pharmaceuticals
Phase 3202—Registry ↗
Oct 26, 2026A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propiona…
NCT06664619 · Asthma
Fp/ABS, FP
TEVA
Teva Branded Pharmaceutical Products R&D LLC
Phase 3649—Registry ↗
Oct 25, 2026Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vacc…
NCT07425392 · Pneumococcal Disease
31-valent pneumococcal conjugate vaccine, PCV20
PCVX
Vaxcyte, Inc.
Phase 3752—Registry ↗
Oct 21, 2026A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza…
NCT07365826 · Pneumococcal Disease
31-valent pneumococcal conjugate vaccine, Seasonal Influenz…
PCVX
Vaxcyte, Inc.
Phase 31,390—Registry ↗
Oct 20, 2026Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the…
NCT03036098 · Urothelial Cancer
Nivolumab, Ipilimumab
BMY
Bristol-Myers Squibb
Phase 31,314postedRegistry ↗
Oct 14, 2026Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
NCT05172726 · Plaque Psoriasis
tapinarof cream, 1%
OGN
Organon and Co
Phase 358—Registry ↗
Oct 9, 2026Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Yea…
NCT02612454 · Atopic Dermatitis
Dupilumab
REGN
Regeneron Pharmaceuticals
Phase 3880—Registry ↗
Sep 28, 2026An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab…
NCT06768671 · Hidradenitis Suppurativa
Sonelokimab
MLTX
MoonLake Immunotherapeutics AG
Phase 335—Registry ↗
Sep 24, 2026Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine…
NCT07135986 · Meningococcal Infection, Healthy Volunteers
MenACYW conjugate vaccine, MenACYW135 polysaccharide vaccine
SNY
Sanofi
Phase 31,602—Registry ↗
Sep 22, 2026A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
NCT07300839 · COVID-19, SARS-COV-2 Infection
BNT162b2 Vaccine, Placebo
BNTX
BioNTech SE
Phase 35,240—Registry ↗
Sep 22, 2026TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (…
NCT04129502 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
TAK-788, Pemetrexed
TAK
Takeda
Phase 3354—Registry ↗
Sep 21, 2026Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on…
NCT06750289 · Eosinophilic Asthma
ICS-LABA, benralizumab
AZN
AstraZeneca
Phase 3130—Registry ↗
Sep 17, 2026Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adult…
NCT07284654 · Pneumococcal Disease
31 valent pneumococcal conjugate vaccine, PCV20
PCVX
Vaxcyte, Inc.
Phase 34,049—Registry ↗
Sep 15, 2026A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle In…
NCT06331299 · Bladder Cancer, Urothelial Carcinoma
UGN-103
URGN
UroGen Pharma Ltd.
Phase 399postedRegistry ↗
Sep 14, 2026Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults…
NCT06050122 · Gorlin Syndrome
Patidegib Topical Gel, Patidegib Topical Gel with no active…
SLGL
Sol-Gel Technologies, Ltd.
Phase 3113—Registry ↗
Sep 14, 2026Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Withou…
NCT03754790 · Hemophilia
Fitusiran
SNY
Genzyme, a Sanofi Company
Phase 3281—Registry ↗
Sep 10, 2026Study of Plozasiran in Adults With Severe Hypertriglyceridemia
NCT06347016 · Severe Hypertriglyceridemia
Plozasiran Injection, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 3311—Registry ↗
Sep 10, 2026A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
NCT06208306 · Chronic Obstructive Pulmonary Disease
Itepekimab (SAR440340), Placebo
SNY
Sanofi
Phase 3669—Registry ↗
Sep 9, 2026C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
NCT06868264 · HEPATITIS C VIRUS CHRONIC INFECTION
Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (S…
AVIR
Atea Pharmaceuticals, Inc.
Phase 3940—Registry ↗
Sep 9, 2026177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Ca…
NCT04689828 · Prostatic Neoplasms
177Lu-PSMA-617, 68Ga-PSMA-11
NVS
Novartis Pharmaceuticals
Phase 3469postedRegistry ↗
Sep 8, 2026Study of Bitopertin in Participants With EPP or XLP (APOLLO)
NCT06910358 · Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyri…
Placebo, DISC-1459
IRON
Disc Medicine, Inc
Phase 3183—Registry ↗
Sep 8, 2026Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
NCT06347133 · Hypertriglyceridemia
Plozasiran Injection, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 31,456—Registry ↗
Sep 7, 2026A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Mu…
NCT03992430 · Muscular Dystrophy, Duchenne
Eteplirsen
SRPT
Sarepta Therapeutics, Inc.
Phase 3160—Registry ↗
Sep 4, 2026A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Ace…
NCT07596173 · Diphtheria-Tetanus-acellular Pertussis Vaccines
dTpa vaccine
GSK
GlaxoSmithKline
Phase 390—Registry ↗
Sep 4, 2026Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)
NCT04652882 · Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm
Tasimelteon, Placebo
VNDA
Vanda Pharmaceuticals
Phase 343—Registry ↗
Sep 3, 2026A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration an…
NCT07032597 · Mid Face Volume Deficit
HArmonyCa Lidocaine Injectable Gel, Restylane® Perlane® Lid…
ABBV
AbbVie
Phase 3252—Registry ↗
Sep 3, 2026A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Mod…
NCT05565560 · Plaque Psoriasis
Apremilast
AMGN
Amgen
Phase 321—Registry ↗
Sep 2, 2026A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injection…
NCT06687980 · Lichen Simplex Chronicus
Dupilumab, Placebo
SNY
Sanofi
Phase 3138—Registry ↗
Aug 31, 2026A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injection…
NCT06687967 · Lichen Simplex Chronicus
Dupilumab, Placebo
SNY
Sanofi
Phase 3142—Registry ↗
Aug 28, 2026A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy,…
NCT05568095 · Advanced Upper Gastrointestinal Tract Adenocarcinoma
Domvanalimab, Zimberelimab
RCUS
Arcus Biosciences, Inc.
Phase 31,040—Registry ↗
Aug 25, 2026A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Sev…
NCT07543380 · Respiratory Syncytial Virus (RSV)
RSVpreF
PFE
Pfizer
Phase 3130—Registry ↗
Aug 25, 2026Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
NCT06347003 · Severe Hypertriglyceridemia
Plozasiran Injection, Placebo
ARWR
Arrowhead Pharmaceuticals
Phase 3446—Registry ↗
Aug 24, 2026Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administer…
NCT04956692 · Non-Small Cell Lung Cancer
Pembrolizumab SC, Pembrolizumab IV
MRK
Merck Sharp & Dohme LLC
Phase 3531postedRegistry ↗
Aug 21, 2026A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-…
NCT07284381 · Dry Eye Disease
ABBV-444, REFRESH OPTIVE UD
ABBV
AbbVie
Phase 3261—Registry ↗
Aug 20, 2026Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to…
NCT05643534 · Irritable Bowel Syndrome With Constipation (IBS-C)
Tenapanor 50 MG, Tenapanor 25 mg bid
ARDX
Ardelyx
Phase 3180—Registry ↗
Aug 19, 2026A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
NCT03762850 · Immunoglobulin A Nephropathy
sparsentan, irbesartan
TVTX
Travere Therapeutics, Inc.
Phase 3406postedRegistry ↗
Aug 17, 2026A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome…
NCT06104124 · Sjogren's Syndrome
Dazodalibep, Placebo
AMGN
Amgen
Phase 3651—Registry ↗

The newest 38 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 3:16 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances